StockIQpro
NASDAQ:SNOA

Sonoma Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Sonoma Pharmaceuticals, Inc.'s revenue grew 36.7% in fiscal 2026 to $19.5M while operating margin rose to −12.6%, its highest in 10 years. Free cash flow was −$4.1M, −21.1% of revenue, and the diluted share count rose 35.7%.Summary generated from Sonoma Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Jun 16, 2026.

Key statistics

Fiscal 2026 from SEC filings. Methodology
Revenue (FY26)$19.5M
Revenue growth+36.7%
Revenue, 5-yr CAGR+0.9%
Gross margin38.0%
Operating margin−12.6%
Net margin−16.3%
ROIC−2221.9%
Return on equity−84.6%
Debt / equity0.07
Free cash flow−$4.1M
FCF margin−21.1%
Share count change+35.7%

Financials

Fiscal years, $M
Item20222023202420252026
Revenue1313131420
Operating income−6−5−5−4−2
Net income−5−5−5−3−3
Free cash flow−4−6−2−0−4

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus